This study is designed to compare the safety and efficacy of ASKC202 combined with Limertinib Versus platinum-based chemotherapy in locally advanced or metastatic NSCLC With MET Amplification/Overexpression after disease progression on EGFR tyrosine kinase inhibitor.
Willing and able to provide signed and dated informed consent;
Patients at least 18 years of age;
Locally advanced or metastatic non-small cell lung cancer (NSCLC);
Objective disease progression following prior EGFR-TKI therapy;
Prior or ongoing treatment with any c-Met target;
Previously received systemic chemotherapy;
Patients requiring continuous use of systemic immunosuppressants or systemic corticosteroids within 2 weeks prior to the first dose.
Patients who underwent other major surgical procedures other than diagnosis or biopsy within 4 weeks prior to the first dose, or who were expected to undergo major surgeries during the study period;